Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

Asthma Clinical Trial

— ORBEX  

Official title:

Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02148796
• Other study ID #: ORBEX-BV2014/06
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 3, 2017
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2023
• Source: University of Arizona
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk infants for 10 days, monthly, for two consecutive years can increase time to occurrence of the first episode of wheezing lower respiratory tract illness (WLRI) during a three year observation period off therapy.

Description:

This is a five year parallel arm, double-blind, placebo-controlled trial for the prevention of WLRI into the third to seventh year of life (30 to 78 mo inclusive) in young children (6-18 months old) at increased risk for asthma. The trial will be divided into 2 periods. During the initial treatment period (first and second years in the study) participants will receive Broncho- Vaxom® (3.5 mg) or placebo for ten days each month for two consecutive years. This period will allow the observation of key secondary outcomes while participants are receiving therapy. The second period (third through fifth years in the study) will be a three year observation of the time to occurrence of the first WLRI episode (primary outcome) while off study drug along with the secondary outcomes noted above. During both the treatment and observation periods, participants will be managed by study physicians using a rescue algorithm applied in the PEAK trial commensurate with the NAEPP Expert Panel Report (EPR) III guidelines.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 822
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Months to 18 Months

Eligibility

Inclusion Criteria:

• Adequate completion of informed consent process with written documentation. The participant's legally acceptable representative must have provided the appropriate written informed consent. Assent forms will not be used due to the age of the participant population; however, for procedures later in the study when participants are older, age appropriate assent will be obtained, if required by local Institutional Review Board (IRB).

• Age: 6-18 months of age inclusive at randomization which means 5 to 17 months of age inclusive on entry into the one month run-in period. At least half of all enrolled children will be between 6 and 12 months of age at randomization.

• Participants will meet at least one of the following criteria, which have been associated with an increased risk of wheezing respiratory illnesses and asthma: a) Parental history of asthma -or- b) Physician-diagnosed atopic dermatitis in the participant - or- c) Physician-diagnosed asthma in a blood sibling aged 4 years or more.

• Participants may be either male or female.

• Participants will have at least one parent/guardian who can communicate with the study staff to allow assessment of study outcomes. All study materials used by parent/guardian will be made available in English and in Spanish.

The child's parent/guardian must have a working direct contact telephone.

Exclusion Criteria:

• Participants may not have had more than two prior WLRI episodes.

• Participants may not have had any SWLRI episodes.

• Participants may not have a physician's diagnosis of asthma.

• Participants may not have a systemic illness (other than allergy) including (but not limited to) recurrent seizures, chronic gastroesophageal reflux (GER) requiring medical treatment, major congenital anomalies, physical and intellectual delay, cerebral palsy, chest surgery, tuberculosis or other chronic infections, primary or secondary immunodeficiency, gastrointestinal malformation or disease or cardiac disorder (except a hemodynamically insignificant atrial septal defect (ASD), ventricular septal defect (VSD) or benign heart murmur).

• Participants may not have been born earlier than 36 weeks of gestation.

• Participants may not have received oxygen for more than 5 days in the neonatal period, or received mechanical ventilation with the exclusion of ventilation during anesthesia for a minor surgical procedure.

• Participants may not have significant neurodevelopmental delay.

• Participants may not be below the 3rd percentile for weight.

• Participants may not have any other chronic lung disease; e.g. chronic lung disease of prematurity (CLDP) or cystic fibrosis.

• Participants may not have a history of any life-threatening respiratory illness that required intubation and mechanical ventilation.

• The participant's family may not be expected to relocate out of study area within 3 years of the initiation of the study.

• Participants may not have received inhaled or systemic corticosteroids for respiratory related illness ever, or for other conditions in the month prior to randomization.

• Participants may not have ever received immunotherapy.

• Participants may not have ever received i.v. gammaglobulins or systemic immunosuppressants.

• Participants may not have received probiotics (Lactobacilli and Bifidobacteria) in medicinal form; (i.e. not including food), regularly for more than 4 months in the 6 to <12 mo age group or 6 months in the 12 to 18 month group prior to enrollment.

• Participant has known sensitivity to any of the study products and any of the ingredients to be administered.

• Participant has previously been randomized in this study. Participants who failed run-in and were not randomized may have study participation terminated and then be re-enrolled for a second run-in period.

• Participant is currently enrolled in or has completed any other investigational device or drug study <30 days prior to screening, or is receiving other investigational agent(s).

• Participant has a significant medical condition(s), anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the participant, or may interfere with study assessments, outcomes, or the ability to provide written informed consent or comply with study procedures, in the Investigator's opinion.

• The one month run-in period will be used to evaluate adherence to study drug administration and electronic communication. At randomization the participant must continue to meet enrolment criteria and also have demonstrated 80% adherence to the placebo during treatment period; i.e. 8 out of 10 days and a75% response rate to weekly mobile phone text queries; i.e. 3 out of 4 weekly text queries.

• Ongoing infection (of any organ system) at the time of randomization. This includes infections that are being adequately treated.

• Unable or unlikely to complete study assessments or the study intervention poses undue risk to patient in the opinion of the Investigator.

• Families will speak English and/or Spanish.

Related Conditions & MeSH terms

• Asthma
• Respiratory Sounds
• Wheezing

Intervention

Drug:
• Broncho-Vaxom (BV)
Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma, Switzerland (OM stands for Omnia Medicamenta) Storage: Store in the original package

Other:
• Placebo
A placebo capsule will be used that will be indistinguishable from the active study drug.

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	Boston Children's Hospital, Harvard University	Boston	Massachusetts
United States	University of North Carolina	Chapel Hill	North Carolina
United States	Cincinnati Children's Hospital & Medical Center	Cincinnati	Ohio
United States	University of Wisconsin	Madison	Wisconsin
United States	Columbia University	New York	New York
United States	University of California San Francisco, Benioff Children's Hospital	Oakland	California
United States	Phoenix Children's Hospital	Phoenix	Arizona
United States	Washington University	Saint Louis	Missouri
United States	University of Arizona	Tucson	Arizona
United States	Children's National Health System	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University of Arizona

Country where clinical trial is conducted

United States, 

References & Publications (58)

Ahanchian H, Jones CM, Chen YS, Sly PD. Respiratory viral infections in children with asthma: do they matter and can we prevent them? BMC Pediatr. 2012 Sep 13;12:147. doi: 10.1186/1471-2431-12-147. — View Citation

Azad MB, Coneys JG, Kozyrskyj AL, Field CJ, Ramsey CD, Becker AB, Friesen C, Abou-Setta AM, Zarychanski R. Probiotic supplementation during pregnancy or infancy for the prevention of asthma and wheeze: systematic review and meta-analysis. BMJ. 2013 Dec 4;347:f6471. doi: 10.1136/bmj.f6471. — View Citation

Becker A, Watson W, Ferguson A, Dimich-Ward H, Chan-Yeung M. The Canadian asthma primary prevention study: outcomes at 2 years of age. J Allergy Clin Immunol. 2004 Apr;113(4):650-6. doi: 10.1016/j.jaci.2004.01.754. — View Citation

Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P, Bisgaard H, Davis GM, Ducharme FM, Eigen H, Gappa M, Gaultier C, Gustafsson PM, Hall GL, Hantos Z, Healy MJ, Jones MH, Klug B, Lodrup Carlsen KC, McKenzie SA, Marchal F, Mayer OH, Merkus PJ, Morris MG, Oostveen E, Pillow JJ, Seddon PC, Silverman M, Sly PD, Stocks J, Tepper RS, Vilozni D, Wilson NM; American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med. 2007 Jun 15;175(12):1304-45. doi: 10.1164/rccm.200605-642ST. No abstract available. — View Citation

Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bonnelykke K, Brasholt M, Heltberg A, Vissing NH, Thorsen SV, Stage M, Pipper CB. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007 Oct 11;357(15):1487-95. doi: 10.1056/NEJMoa052632. — View Citation

Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol. 2010 Nov;10(11):797-803. doi: 10.1038/nri2869. — View Citation

Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T, Haahtela T, Lambrecht BN, Postma DS, Sunyer J, Valenta R, Akdis CA, Annesi-Maesano I, Arno A, Bachert C, Ballester F, Basagana X, Baumgartner U, Bindslev-Jensen C, Brunekreef B, Carlsen KH, Chatzi L, Crameri R, Eveno E, Forastiere F, Garcia-Aymerich J, Guerra S, Hammad H, Heinrich J, Hirsch D, Jacquemin B, Kauffmann F, Kerkhof M, Kogevinas M, Koppelman GH, Kowalski ML, Lau S, Lodrup-Carlsen KC, Lopez-Botet M, Lotvall J, Lupinek C, Maier D, Makela MJ, Martinez FD, Mestres J, Momas I, Nawijn MC, Neubauer A, Oddie S, Palkonen S, Pin I, Pison C, Rance F, Reitamo S, Rial-Sebbag E, Salapatas M, Siroux V, Smagghe D, Torrent M, Toskala E, van Cauwenberge P, van Oosterhout AJ, Varraso R, von Hertzen L, Wickman M, Wijmenga C, Worm M, Wright J, Zuberbier T. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy. 2011 May;66(5):596-604. doi: 10.1111/j.1398-9995.2010.02534.x. Epub 2011 Jan 24. — View Citation

Carroll KN, Gebretsadik T, Griffin MR, Wu P, Dupont WD, Mitchel EF, Enriquez R, Hartert TV. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics. 2008 Jul;122(1):58-64. doi: 10.1542/peds.2007-2087. — View Citation

Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1403-6. doi: 10.1164/ajrccm.162.4.9912111. — View Citation

Collet JP, Ducruet T, Kramer MS, Haggerty J, Floret D, Chomel JJ, Durr F. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicreche Research Group. Pediatr Infect Dis J. 1993 Aug;12(8):648-52. doi: 10.1097/00006454-199308000-00005. — View Citation

De Prost Y - Clinical Study Report (BV-2002/1) Multicentric, randomized, double-blind, placebo-controlled study of the efficacy and safety of Broncho-Vaxom® (OM-85 BV) in children suffering from atopic dermatitis. - Clinical Study Report (30 January 2008).

Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJ. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004974. doi: 10.1002/14651858.CD004974.pub2. — View Citation

Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrlander C, Heederik D, Piarroux R, von Mutius E; GABRIELA Transregio 22 Study Group. Exposure to environmental microorganisms and childhood asthma. N Engl J Med. 2011 Feb 24;364(8):701-9. doi: 10.1056/NEJMoa1007302. — View Citation

Evans SE, Scott BL, Clement CG, Larson DT, Kontoyiannis D, Lewis RE, Lasala PR, Pawlik J, Peterson JW, Chopra AK, Klimpel G, Bowden G, Hook M, Xu Y, Tuvim MJ, Dickey BF. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol. 2010 Jan;42(1):40-50. doi: 10.1165/rcmb.2008-0260OC. Epub 2009 Mar 27. — View Citation

FDA Center for Drug Evaluation and Research (CDER) - Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children. Guidance for Industry: March 2007.

Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, Johnson DW, Klassen TP, Hartling L. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2013 Jun 4;2013(6):CD004878. doi: 10.1002/14651858.CD004878.pub4. — View Citation

Gadomski AM, Brower M. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD001266. doi: 10.1002/14651858.CD001266.pub2. — View Citation

Guilbert TW, Morgan WJ, Krawiec M, Lemanske RF Jr, Sorkness C, Szefler SJ, Larsen G, Spahn JD, Zeiger RS, Heldt G, Strunk RC, Bacharier LB, Bloomberg GR, Chinchilli VM, Boehmer SJ, Mauger EA, Mauger DT, Taussig LM, Martinez FD; Prevention of Early Asthma in Kids Study,Childhood Asthma Research and Education Network. The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network. Control Clin Trials. 2004 Jun;25(3):286-310. doi: 10.1016/j.cct.2004.03.002. — View Citation

Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, Bacharier LB, Lemanske RF Jr, Strunk RC, Allen DB, Bloomberg GR, Heldt G, Krawiec M, Larsen G, Liu AH, Chinchilli VM, Sorkness CA, Taussig LM, Martinez FD. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006 May 11;354(19):1985-97. doi: 10.1056/NEJMoa051378. — View Citation

Halterman JS, Aligne CA, Auinger P, McBride JT, Szilagyi PG. Inadequate therapy for asthma among children in the United States. Pediatrics. 2000 Jan;105(1 Pt 3):272-6. — View Citation

Holt PG, Sly PD, Martinez FD, Weiss ST, Bjorksten B, von Mutius E, Wahn U. Drug development strategies for asthma: in search of a new paradigm. Nat Immunol. 2004 Jul;5(7):695-8. doi: 10.1038/ni0704-695. — View Citation

Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, Printz MC, Lee WM, Shult PA, Reisdorf E, Carlson-Dakes KT, Salazar LP, DaSilva DF, Tisler CJ, Gern JE, Lemanske RF Jr. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008 Oct 1;178(7):667-72. doi: 10.1164/rccm.200802-309OC. Epub 2008 Jun 19. — View Citation

Jackson DJ. The role of rhinovirus infections in the development of early childhood asthma. Curr Opin Allergy Clin Immunol. 2010 Apr;10(2):133-8. doi: 10.1097/ACI.0b013e3283352f7c. — View Citation

Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996 Feb;5(1):35-46. doi: 10.1007/BF00435967. — View Citation

Klassen AF, Landgraf JM, Lee SK, Barer M, Raina P, Chan HW, Matthew D, Brabyn D. Health related quality of life in 3 and 4 year old children and their parents: preliminary findings about a new questionnaire. Health Qual Life Outcomes. 2003 Dec 22;1:81. doi: 10.1186/1477-7525-1-81. — View Citation

Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, Sly PD. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007 May;119(5):1105-10. doi: 10.1016/j.jaci.2006.12.669. Epub 2007 Mar 13. — View Citation

Lau S. What is new in the prevention of atopy and asthma? Curr Opin Allergy Clin Immunol. 2013 Apr;13(2):181-6. doi: 10.1097/ACI.0b013e32835eb7b1. — View Citation

Maier RM, Palmer MW, Andersen GL, Halonen MJ, Josephson KC, Maier RS, Martinez FD, Neilson JW, Stern DA, Vercelli D, Wright AL. Environmental determinants of and impact on childhood asthma by the bacterial community in household dust. Appl Environ Microbiol. 2010 Apr;76(8):2663-7. doi: 10.1128/AEM.01665-09. Epub 2010 Feb 12. — View Citation

Mansbach JM, Camargo CA Jr. Respiratory viruses in bronchiolitis and their link to recurrent wheezing and asthma. Clin Lab Med. 2009 Dec;29(4):741-55. doi: 10.1016/j.cll.2009.07.011. — View Citation

Martinez FD. New insights into the natural history of asthma: primary prevention on the horizon. J Allergy Clin Immunol. 2011 Nov;128(5):939-45. doi: 10.1016/j.jaci.2011.09.020. — View Citation

Martinez FD. The connection between early life wheezing and subsequent asthma: The viral march. Allergol Immunopathol (Madr). 2009 Sep-Oct;37(5):249-51. doi: 10.1016/j.aller.2009.06.008. — View Citation

McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting beta(2)-adrenergic receptor agonists. Pediatrics. 2011 Nov;128(5):e1147-54. doi: 10.1542/peds.2010-1720. Epub 2011 Oct 24. — View Citation

Mitchell H, Senturia Y, Gergen P, Baker D, Joseph C, McNiff-Mortimer K, Wedner HJ, Crain E, Eggleston P, Evans R 3rd, Kattan M, Kercsmar C, Leickly F, Malveaux F, Smartt E, Weiss K. Design and methods of the National Cooperative Inner-City Asthma Study. Pediatr Pulmonol. 1997 Oct;24(4):237-52. doi: 10.1002/(sici)1099-0496(199710)24:43.0.co;2-h. — View Citation

Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, Evans R 3rd, Stout J, Malindzak G, Smartt E, Plaut M, Walter M, Vaughn B, Mitchell H; Inner-City Asthma Study Group. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004 Sep 9;351(11):1068-80. doi: 10.1056/NEJMoa032097. — View Citation

Navarro RP, Schaecher KL, Rice GK. Asthma management guidelines: updates, advances, and new options. J Manag Care Pharm. 2007 Aug;13(6 Suppl D):S3-11; quiz S12-3. doi: 10.18553/jmcp.2007.13.s6-d.1. — View Citation

Navarro S, Cossalter G, Chiavaroli C, Kanda A, Fleury S, Lazzari A, Cazareth J, Sparwasser T, Dombrowicz D, Glaichenhaus N, Julia V. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol. 2011 Jan;4(1):53-65. doi: 10.1038/mi.2010.51. Epub 2010 Sep 1. — View Citation

NHIS (2011)] National Health Interview Survey Data - Current Asthma Population Estimates. National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention Hyattsville, MD: http://www.cdc.gov/asthma/nhis/2011/data.htm

NHLBI. National Asthma Education and Prevention Program: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma; NIH Publication Number 08-5846. October 2007.

Parola C, Salogni L, Vaira X, Scutera S, Somma P, Salvi V, Musso T, Tabbia G, Bardessono M, Pasquali C, Mantovani A, Sozzani S, Bosisio D. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PLoS One. 2013 Dec 30;8(12):e82867. doi: 10.1371/journal.pone.0082867. eCollection 2013. — View Citation

Pasquali C, Salami O, Taneja M, Gollwitzer ES, Trompette A, Pattaroni C, Yadava K, Bauer J, Marsland BJ. Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract. Front Med (Lausanne). 2014 Oct 30;1:41. doi: 10.3389/fmed.2014.00041. eCollection 2014. — View Citation

Principi N - Clinical Study Report (BV-2005/01) Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom in Children Suffering from Recurrent Upper Respiratory Tract Infections. - Clinical Study Report (2 October 2012a).

Principi N - Clinical Study Report (EBV09/01) Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom® Drops in Children Suffering from Recurrent Respiratory Tract Infections. - Clinical Study Report (23 October 2012b).

Razi CH, Harmanci K, Abaci A, Ozdemir O, Hizli S, Renda R, Keskin F. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol. 2010 Oct;126(4):763-9. doi: 10.1016/j.jaci.2010.07.038. — View Citation

Riedler J, Braun-Fahrlander C, Eder W, Schreuer M, Waser M, Maisch S, Carr D, Schierl R, Nowak D, von Mutius E; ALEX Study Team. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet. 2001 Oct 6;358(9288):1129-33. doi: 10.1016/S0140-6736(01)06252-3. — View Citation

Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr. 2010 Feb;6(1):5-12. doi: 10.1007/s12519-010-0001-x. Epub 2010 Feb 9. — View Citation

Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000 May;161(5):1501-7. doi: 10.1164/ajrccm.161.5.9906076. — View Citation

Sly PD, Kusel M, Holt PG. Do early-life viral infections cause asthma? J Allergy Clin Immunol. 2010 Jun;125(6):1202-5. doi: 10.1016/j.jaci.2010.01.024. Epub 2010 Mar 20. — View Citation

Spertini F - Clinical Study Report (BV-2007/03) Efficacy of Broncho-Vaxom® in Allergic Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study. - Clinical Study Report (31 July 2009)

Strickland DH, Holt PG. T regulatory cells in childhood asthma. Trends Immunol. 2011 Sep;32(9):420-7. doi: 10.1016/j.it.2011.06.010. Epub 2011 Jul 27. — View Citation

Strickland DH, Judd S, Thomas JA, Larcombe AN, Sly PD, Holt PG. Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. Mucosal Immunol. 2011 Jan;4(1):43-52. doi: 10.1038/mi.2010.43. Epub 2010 Jul 28. — View Citation

Thorburn K, Harigopal S, Reddy V, Taylor N, van Saene HK. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax. 2006 Jul;61(7):611-5. doi: 10.1136/thx.2005.048397. Epub 2006 Mar 14. — View Citation

Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS One. 2009;4(1):e4176. doi: 10.1371/journal.pone.0004176. Epub 2009 Jan 12. — View Citation

von Mutius E, Vercelli D. Farm living: effects on childhood asthma and allergy. Nat Rev Immunol. 2010 Dec;10(12):861-8. doi: 10.1038/nri2871. Epub 2010 Nov 9. Erratum In: Nat Rev Immunol. 2019 Sep;19(9):594. — View Citation

Wildfire JJ, Gergen PJ, Sorkness CA, Mitchell HE, Calatroni A, Kattan M, Szefler SJ, Teach SJ, Bloomberg GR, Wood RA, Liu AH, Pongracic JA, Chmiel JF, Conroy K, Rivera-Sanchez Y, Busse WW, Morgan WJ. Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents. J Allergy Clin Immunol. 2012 Mar;129(3):694-701. doi: 10.1016/j.jaci.2011.12.962. Epub 2012 Jan 12. — View Citation

Yasuda Y, Matsumura Y, Kasahara K, Ouji N, Sugiura S, Mikasa K, Kita E. Microbial exposure early in life regulates airway inflammation in mice after infection with Streptococcus pneumoniae with enhancement of local resistance. Am J Physiol Lung Cell Mol Physiol. 2010 Jan;298(1):L67-78. doi: 10.1152/ajplung.00193.2009. Epub 2009 Sep 25. — View Citation

Yoo J, Tcheurekdjian H, Lynch SV, Cabana M, Boushey HA. Microbial manipulation of immune function for asthma prevention: inferences from clinical trials. Proc Am Thorac Soc. 2007 Jul;4(3):277-82. doi: 10.1513/pats.200702-033AW. — View Citation

Yunginger JW, Reed CE, O'Connell EJ, Melton LJ 3rd, O'Fallon WM, Silverstein MD. A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. Am Rev Respir Dis. 1992 Oct;146(4):888-94. doi: 10.1164/ajrccm/146.4.888. — View Citation

Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, Strunk RC, Covar R, Szefler SJ, Boehmer S, Jackson DJ, Sorkness CA, Gern JE, Kelly HW, Friedman NJ, Mellon MH, Schatz M, Morgan WJ, Chinchilli VM, Raissy HH, Bade E, Malka-Rais J, Beigelman A, Taussig LM; CARE Network of the National Heart, Lung, and Blood Institute. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med. 2011 Nov 24;365(21):1990-2001. doi: 10.1056/NEJMoa1104647. — View Citation

* Note: There are 58 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The proportion of episode free days (EFD) annualized for each year of study.	shortness of breath, cough, chest retraction or tightness; 2) No unscheduled medical visits for respiratory symptoms AND 3) No use of any asthma medications, including albuterol before exercise.	Treatment (2 yr) and observation periods
Other	Time to first systemic corticosteroid course	Time to first systemic corticosteroid course	Treatment (2 yr) and observation periods
Other	Number of systemic corticosteroid courses	Number of systemic corticosteroid courses	Treatment (2 yr) and observation periods
Other	Cumulative systemic corticosteroid courses	Cumulative systemic corticosteroid courses	Treatment (2 yr) and observation periods
Other	Cumulative systemic corticosteroid dose	Cumulative systemic corticosteroid dose	Treatment (2 yr) and observation periods
Other	Cumulative time receiving controller inhaled corticosteroid (ICS)	Cumulative time receiving controller inhaled corticosteroid (ICS)	Treatment (2 yr) and observation periods
Other	Cumulative does of controller ICS	Cumulative does of controller ICS	Treatment (2 yr) and observation periods
Other	Cumulative time of receiving any controller medication (ICS, systemic steroid, or montelukast)	Cumulative time of receiving any controller medication (ICS, systemic steroid, or montelukast)	Treatment (2 yr) and observation periods
Other	Days with albuterol use	Days with albuterol use	Treatment (2 yr) and observation periods
Other	Urgent care/Emergency Department (ED)/Office visits/hospitalizations for respiratory illness analyzed separately and combined variable	Urgent care/ED/Office visits/hospitalizations for respiratory illness analyzed separately and combined variable	Treatment (2 yr) and observation periods
Other	Change in height and weight from baseline	Change in height and weight from baseline	Treatment (2 yr) and observation periods
Primary	The time to the occurrence of the first WLRI episode in the observation period while not receiving study drug	The time to the occurrence of the first WLRI episode in the observation period while not receiving study drug	ages 30 to 42 months at the end of treatment; ages 66 to 78 months at completion
Secondary	The time to first WLRI during the two treatment years while receiving study drug	The time to first WLRI during the two treatment years while receiving study drug	ages 6 to 18 months at start of therapy; ages 30 to 42 months at completion
Secondary	The annualized rate of WLRI episodes during the two years while receiving study drug	The annualized rate of WLRI episodes during the two years while receiving study drug	ages 6 to 18 months at start of therapy; ages 30 to 42 months at completion
Secondary	The annualized rate of WLRI episodes during the observation period while not receiving study drug	The annualized rate of WLRI episodes during the observation period while not receiving study drug	ages 30 to 42 months at the end of treatment; ages 66 to 78 months at completion
Secondary	The annualized rate of severe wheezing respiratory tract illness (SWLRI) episodes during the two treatment years while receiving study drug.	SWLRI episodes are defined as cough and wheezing > 24 hours AND any one of the following: Use of more than 6 albuterol treatments in =48 hours.; Unscheduled care visit for acute wheezing in doctor's office, urgent care or emergency department -or- hospitalization for wheezing.; Use of systemic corticosteroid prescribed by a licensed medical provider for a wheezing illness with or without a clinical visit.; The annualized rate of SWLRI episodes during the two years while receiving study drug.	ages 6 to 18 months at start of therapy; ages 30 to 42 months at completion
Secondary	The annualized rate of severe wheezing respiratory tract illness (SWLRI) episodes during the observation period while not receiving study drug.	The annualized rate of severe wheezing respiratory tract illness (SWLRI) episodes during the observation period while not receiving study drug.	ages 30 to 42 months at the end of treatment; ages 66 to 78 months at completion
Secondary	Asthma at the end of the observation period	Asthma at the end of the observation period defined by any of the following three elements: (a) a health care provider diagnosis of asthma with reports of: at least one episode of wheezing or asthma in the previous year or asthma controllers prescribed for at least 6 months during the previous year; or (b) >3 episodes of wheezing during the previous year 38 ("frequent wheezers"); or (c) any wheezing during the third observation year in children who wheezed during the first three years of life ("persistent wheezers").	ages 30 to 42 months at the end of treatment; ages 66 to 78 months at completion
Secondary	Safety and tolerability of Broncho-Vaxom® while receiving study drug during the two year treatment period.	Safety and tolerability of Broncho-Vaxom® while receiving study drug during the two year treatment period	ages 6 to 18 months at start of therapy; ages 30 to 42 months at completion
Secondary	Safety and tolerability of Broncho-Vaxom® while receiving study drug during the observation period.	Safety and tolerability of Broncho-Vaxom® while receiving study drug during the observation period, after study drug has been stopped.	ages 30 to 42 months at the end of treatment; ages 66 to 78 months at completion